ANDA 214230, held by Mankind Pharma. Sugammadex Sodium.
As of Nov 16, 2026, ANDA 214230 (Sugammadex Sodium), held by Mankind Pharma, was first approved by FDA on Jul 28, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 28, 2026 | Original application | Approved |
| Sugammadex SodiumEQ 200MG BASE/2ML (EQ 100MG BASE/ML) · solution;intravenous | Sugammadex Sodium | Rx |
| Sugammadex SodiumEQ 500MG BASE/5ML (EQ 100MG BASE/ML) · solution;intravenous | Sugammadex Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters